Cranium; Deformity

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Cranium; Deformity trials you may qualify for

100

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 39 trials

RecruitingPhase 2

NCT04374305

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwan…

United States109 participantsStarted 2020-06-20

Treatment: Brigatinib, Neratinib

RecruitingNot Applicable

NCT00598351

Natural History Study of Patients With Neurofibromatosis Type 2

Objective With this prospective natural experiment trial on neurofibromatosis type 2 (NF2) study, we hope to understand the factors leading to tumor progressio…

United States269 participantsStarted 2008-03-21

RecruitingNot Applicable

NCT03050268

Familial Investigations of Childhood Cancer Predisposition

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receiv…

United States1,500 participantsStarted 2017-04-06

RecruitingPhase 1/2

NCT06970106

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

This study aims to gather safety data and determine the optimal dosing regimen for PYC-001 in participants with confirmed OPA1 mutation-associated ADOA. Approxi…

Australia, New Zealand18 participantsStarted 2025-09-30

Treatment: PYC-001

RecruitingNot Applicable

NCT06724029

Neurosurgical Outcome Network

The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. T…

Italy4,500 participantsStarted 2022-12-05

RecruitingPhase 3

NCT06891443

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjec…

United States32 participantsStarted 2025-06-04

Treatment: sepofarsen, Placebo IVT

All recent trials (100 shown)

Not Yet RecruitingPhase 4

NCT07240649

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially…

Location not specified100 participantsStarted 2026-08

Treatment: Hyperbaric oxygen treatment (HBOT), 100% Oxygen

CompletedPhase 2

NCT03717909

Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome

This trial aims to investigate the efficacy, safety and tolerability of sodium valproate in the treatment of patients with Wolfram syndrome. 70 paediatric and a…

France, Poland +2 more63 participantsStarted 2018-12-28

Treatment: Sodium Valproate 200Mg E/C Tablet, Sodium Valproate matched placebo

Cranium; Deformity

Trial phase breakdown

Trial status

Actively recruiting — 39 trials

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Natural History Study of Patients With Neurofibromatosis Type 2

Familial Investigations of Childhood Cancer Predisposition

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

Neurosurgical Outcome Network

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

All recent trials (100 shown)

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome

Trial phase breakdown

Trial status

Actively recruiting — 39 trials

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

Natural History Study of Patients With Neurofibromatosis Type 2

Familial Investigations of Childhood Cancer Predisposition

Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)

Neurosurgical Outcome Network

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

All recent trials (100 shown)

Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications

Efficacy and Safety Trial of Sodium Valproate, in Paediatric and Adult Patients With Wolfram Syndrome

Natural History Study of Patients With Neurofibromatosis Type I

Clinical Study of the Treatment of Chiari Malformation Combined With Type II Skull Base Depression

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced…

MElanoma Research Lymph Node Prediction Implementation National_001

Facial iD Customized Mandible Reconstruction Plates

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

AMX0035 in Adult Patients With Wolfram Syndrome

Study on Moebius Syndrome and Congenital Facial Weakness Disorders

Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)

Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Sc…

3D-Printed Patient-Specific Surgical Plates Versus Conventional Surgical Plates in Jaw Reconstruction

RESCUE and REVERSE Long-term Follow-up

Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients

EAP_GS010_single Patient

REALITY LHON Registry

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation…